Shanghai, China

Yunyan Kuang

This inventor holds 2 USPTO granted patents. Top assignee: Uwm Research Foundation, Inc.. Active years: 2014-2015.


% Patents Active = 50.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014-2015

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Yunyan Kuang

Introduction

Yunyan Kuang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of anti-cancer agents. With a total of 2 patents to his name, Kuang is dedicated to advancing medical science and improving patient outcomes.

Latest Patents

Yunyan Kuang's latest patents focus on the development of anti-cancer agents. These patents describe compounds that can be selectively activated to produce active anti-cancer agents specifically within tumor cells. Additionally, the patents disclose pharmaceutical compositions that comprise these compounds, along with methods for treating cancer using them. This innovative approach has the potential to revolutionize cancer therapies and provide more effective treatment options for patients.

Career Highlights

Kuang is currently associated with the UWM Research Foundation, Inc., where he continues to explore new avenues in cancer research. His work is characterized by a commitment to scientific excellence and a passion for finding solutions to complex medical challenges.

Collaborations

Some of his notable coworkers include Wenbing Chen and Sheng Cao, who contribute to the collaborative efforts in research and development at the foundation.

Conclusion

Yunyan Kuang's work in developing anti-cancer agents showcases his dedication to innovation in the medical field. His contributions are paving the way for more effective cancer treatments, ultimately benefiting patients worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…